Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2016

01-04-2016 | Research Article

Free phenytoin assessment in patients: measured versus calculated blood serum levels

Authors: Andrea Tobler, Raphael Hösli, Stefan Mühlebach, Andreas Huber

Published in: International Journal of Clinical Pharmacy | Issue 2/2016

Login to get access

Abstract

Background Total serum drug levels are routinely determined for the therapeutic drug monitoring of selected, difficult-to-dose drugs. For some of these drugs, however, knowledge of the free fraction is necessary to adapt correct dosing. Phenytoin, with its non-linear pharmacokinetics, >90 % albumin binding and slow elimination rate, is such a drug requiring individualization in patients, especially if rapid intravenous loading and subsequent dose adaptation is needed. In a prior long-term investigation, we showed the excellent performance of pharmacy-assisted Bayesian forecasting support for optimal dosing in hospitalized patients treated with phenytoin. In a subgroup analysis, we evaluated the suitability of the Sheiner-Tozer algorithm to calculate the free phenytoin fraction in hypoalbuminemic patients. Objective To test the usefulness of the Sheiner-Tozer algorithm for the correct estimation of the free phenytoin concentrations in hospitalized patients. Setting A Swiss tertiary care hospital. Method Free phenytoin plasma concentration was calculated from total phenytoin concentration in hypoalbuminemic patients and compared with the measured free phenytoin. The patients were separated into a low (35 ≤ albumin ≥ 25 g/L) and a very low group (albumin <25 g/L) for comparing and statistically analyzing the calculated and the measured free phenytoin concentration. Main outcome measures Calculated and the measured free phenytoin concentration. Results The calculated (1.2 mg/L (SD = 0.7) and the measured (1.1 mg/L (SD = 0.5) free phenytoin concentration correlated. The mean difference in the low and the very low albumin group was: 0.10 mg/L (SD = 1.4) (n = 11) and 0.13 mg/L (SD = 0.24) (n = 12), respectively. Although the variability of the data could be a bias, no statistically significant difference between the groups was found: t test (p = 0.78), the Passing–Bablok regression, the Spearman’s rank correlation coefficient of r = 0.907 and p = 0.00. The Bland–Altman plot including the regression analysis revealed no systematic differences between the calculated and the measured value [M = 0.11 (SD = 0.28)]. Conclusion In absence of a free phenytoin plasma concentration measurement also in hypoalbuminemic patients, the Sheiner-Tozer algorithm represents a useful tool to assist therapeutic monitoring to calculate or control free phenytoin by using total phenytoin and the albumin concentration.
Literature
1.
go back to reference Bullock MR, Povlishock JT. Guidelines for the management of severe traumatic brain injury. Editor’s Commentary. J Neurotrauma. 2007;24 Suppl 1:2 p (preceding S1. Erratum in: J Neurotrauma. 2008;25(3):276–8). Bullock MR, Povlishock JT. Guidelines for the management of severe traumatic brain injury. Editor’s Commentary. J Neurotrauma. 2007;24 Suppl 1:2 p (preceding S1. Erratum in: J Neurotrauma. 2008;25(3):276–8).
2.
go back to reference Evans WE, Oellerich M, Holt DW. Drug monitoring, Leitfaden für die klinische Praxis. 2nd ed. Wiesbaden: Abbott; 1994. Evans WE, Oellerich M, Holt DW. Drug monitoring, Leitfaden für die klinische Praxis. 2nd ed. Wiesbaden: Abbott; 1994.
4.
go back to reference Adam D, Büch HP, Büch U, Christ W, Coper H, Dörfler H, et al. Allgemeine und Spezielle Pharmakologie und Toxikologie. 5th ed. Mannheim: Wissenschaftsverlag; 1987. Adam D, Büch HP, Büch U, Christ W, Coper H, Dörfler H, et al. Allgemeine und Spezielle Pharmakologie und Toxikologie. 5th ed. Mannheim: Wissenschaftsverlag; 1987.
5.
go back to reference Schaefer U, Höchner P, Karrer C. Arzneimittel-Kompendium der Schweiz. 32nd ed. Basel: Documed AG; 2011. Schaefer U, Höchner P, Karrer C. Arzneimittel-Kompendium der Schweiz. 32nd ed. Basel: Documed AG; 2011.
6.
go back to reference Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977;5(6):579–96.CrossRefPubMed Martin E, Tozer TN, Sheiner LB, Riegelman S. The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm. 1977;5(6):579–96.CrossRefPubMed
7.
go back to reference Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol. 2009;65(2):109–19.CrossRefPubMed Queckenberg C, Fuhr U. Influence of posture on pharmacokinetics. Eur J Clin Pharmacol. 2009;65(2):109–19.CrossRefPubMed
8.
9.
go back to reference Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med. 1999;123(9):822–3.PubMed Soldin SJ. Free drug measurements. When and why? An overview. Arch Pathol Lab Med. 1999;123(9):822–3.PubMed
10.
go back to reference Kumps AH. Therapeutic drug monitoring: a comprehensive and critical review of analytical methods for anticonvulsive drugs. J Neurol. 1982;228(1):1–16.CrossRefPubMed Kumps AH. Therapeutic drug monitoring: a comprehensive and critical review of analytical methods for anticonvulsive drugs. J Neurol. 1982;228(1):1–16.CrossRefPubMed
11.
go back to reference Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99(2):133–40.CrossRefPubMed Joerger M, Huitema AD, Boogerd W, van der Sande JJ, Schellens JH, Beijnen JH. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic Clin Pharmacol Toxicol. 2006;99(2):133–40.CrossRefPubMed
12.
go back to reference Zielmann S, Mielck F, Kahl R, Kazmaier S, Sydow M, Kolk J, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit. 1994;16(2):139–44.CrossRefPubMed Zielmann S, Mielck F, Kahl R, Kazmaier S, Sydow M, Kolk J, et al. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit. 1994;16(2):139–44.CrossRefPubMed
13.
go back to reference Johansen K, Krogh M, Andresen AT, Christophersen AS, Lehne G, Rasmussen KE. Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;669(2):281–8.CrossRefPubMed Johansen K, Krogh M, Andresen AT, Christophersen AS, Lehne G, Rasmussen KE. Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1995;669(2):281–8.CrossRefPubMed
14.
go back to reference Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit. 1996;18(1):97–9.CrossRefPubMed Dasgupta A, Timmerman TG. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera. Ther Drug Monit. 1996;18(1):97–9.CrossRefPubMed
15.
go back to reference Tobler A, Mühlebach S. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013;35(5):790–7.CrossRefPubMed Tobler A, Mühlebach S. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients. Int J Clin Pharm. 2013;35(5):790–7.CrossRefPubMed
17.
go back to reference Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles in therapeutics. New York: Macmillan; 1978. p. 71–109. Sheiner LB, Tozer TN. Clinical pharmacokinetics: the use of plasma concentrations of drugs. In: Melmon KL, Morelli HF, editors. Clinical pharmacology: basic principles in therapeutics. New York: Macmillan; 1978. p. 71–109.
18.
go back to reference Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem. 1983;21(11):709–20.PubMed Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J Clin Chem Clin Biochem. 1983;21(11):709–20.PubMed
19.
go back to reference Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother. 1995;29(7–8):667–70.PubMed Dager WE, Inciardi JF, Howe TL. Estimating phenytoin concentrations by the Sheiner-Tozer method in adults with pronounced hypoalbuminemia. Ann Pharmacother. 1995;29(7–8):667–70.PubMed
20.
go back to reference Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J. 2009;50(4):517–20.CrossRefPubMedPubMedCentral Hong JM, Choi YC, Kim WJ. Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients. Yonsei Med J. 2009;50(4):517–20.CrossRefPubMedPubMedCentral
21.
go back to reference Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7(5):434–9.CrossRefPubMed Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. Pediatr Crit Care Med. 2006;7(5):434–9.CrossRefPubMed
22.
go back to reference Krasowski MD, Penrod LE. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak. 2012;14(12):7.CrossRef Krasowski MD, Penrod LE. Clinical decision support of therapeutic drug monitoring of phenytoin: measured versus adjusted phenytoin plasma concentrations. BMC Med Inform Decis Mak. 2012;14(12):7.CrossRef
23.
go back to reference von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28(11):1391–400.CrossRef von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. Pharmacotherapy. 2008;28(11):1391–400.CrossRef
Metadata
Title
Free phenytoin assessment in patients: measured versus calculated blood serum levels
Authors
Andrea Tobler
Raphael Hösli
Stefan Mühlebach
Andreas Huber
Publication date
01-04-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 2/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0241-x

Other articles of this Issue 2/2016

International Journal of Clinical Pharmacy 2/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.